PIDOTIMOD

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H12N2O4S
Molecular Weight	244.268
Optical Activity	( - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)[C@@H]1CSCN1C(=O)[C@@H]2CCC(=O)N2

InChI

InChIKey=UUTKICFRNVKFRG-WDSKDSINSA-N

InChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C9H12N2O4S
Molecular Weight	244.268
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.thepharmaletter.com/article/focus-on-pidotimod-a-new-biological-response-modifier
Curator's Comment: Description was created based on several sources, including http://www.mims.com/india/drug/info/pidotimod?mtype=generic http://flipper.diff.org/app/pathways/3840

Pidotimod is a synthetic dipeptide with immunomodulatory properties. An immunostimulant used in patients with cell-mediated immunodepression during resp and urinary tract infections. In vitro and in vivo laboratory studies show that treatment with pidotimod causes a significant induction of macrophage and neutrophil polymorphonuclear activity, which is characterized by an increase in spontaneous chemotaxis, superoxide anion production and phagocytosis. Several placebo-controlled trials of the drug have been carried out in various indications such as recurrent respiratory, pharyngotonsillar and urinary infections in children, and in adults with exacerbations of chronic bronchitis. For example, in 120 children with recurrent respiratory infections, pidotimod reduced relapse by 35%, hospitalization by 86% and antibiotic use by 47% compared to placebo.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
NACHT, LRR and PYD domains-containing protein 12 1 Target ID: P59046 Gene ID: 91662.0 Gene Symbol: NLRP12 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25620184	Activator 1447
Toll-like receptor 2 1 Target ID: CHEMBL4163 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23663325	Activator 1447
Interleukin-2 receptor alpha chain 1 Target ID: CHEMBL1778 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7857357	Activator 1447
natural killer cell mediated cytotoxicity 1 Target ID: GO:0042267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1294620	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Respiratory tract infections 85 Sources: http://www.mims.com/india/drug/info/pidotimod?mtype=generic	Primary		Approved 8583	Pidotimod Approved Use Pidotimod is an immunostimulant used in patients with cell-mediated immunodepression during respiratory and urinary tract infections.
Urinary tract infections 207 Sources: http://www.mims.com/india/drug/info/pidotimod?mtype=generic	Primary		Approved 8583	Pidotimod Approved Use Pidotimod is an immunostimulant used in patients with cell-mediated immunodepression during respiratory and urinary tract infections.

C_max

Value	Dose	Co-administered	Analyte	Population
5.57 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19604731/	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:		PIDOTIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
25.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19604731/	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:		PIDOTIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19604731/	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:		PIDOTIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
96% REVIEW https://mansapublishers.com/index.php/IJCH/article/view/2111			PIDOTIMOD plasma	Homo sapiens

Doses

Dose	Population	Adverse events
800 mg 1 times / day multiple, oral Studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32711565/	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/32711565/	Sources: https://pubmed.ncbi.nlm.nih.gov/32711565/

PubMed

Title	Date	PubMed
Pidotimod: the state of art.	2015	25999796
Complementary treatment with oral pidotimod plus vitamin C after laser vaporization for female genital warts: a prospective study.	2010-10-16	20945819
Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of adefovir in human plasma and its application to a pharmacokinetic study.	2010-08-01	20630813
Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level.	2009-11	19712757
High-performance liquid chromatography-tandem mass spectrometry for the determination of pidotimod in human plasma and its application to a pharmacokinetic study.	2009-08-15	19604731
Pidotimod: a reappraisal.	2009-06-10	19505378
Synergistic immunostimulatory effect of pidotimod and red ginseng acidic polysaccharide on humoral immunity of immunosuppressed mice.	2008-12	19177908
Henoch-Schönlein purpura associated with pidotimod therapy.	2008-10-24	18799074
Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression.	2008-09	18806958
[Comparative meta-analysis of immunoestimulant agents used in pediatric patients in Mexico].	2005-06-17	15957470
Urinary tract infection in children.	2005-06	16135271
Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children.	2004	15260461
[Therapy with cytokines and thymic factors in a complicated case of common variable immunodeficiency].	2003-11-25	14631592
Clinical evaluation and changes of the respiratory epithelium function after administration of Pidotimod in Greek children with recurrent respiratory tract infections.	2002-08	12131867
[Pidotimod in recurring respiratory infection in children with allergic rhinitis, asthma, or both conditions].	2002-07-03	12092522

Patents

Sample Use Guides

In Vivo Use Guide

Take this medication by mouth, usually 2 to 3 times daily with a full glass of water (8 ounces or 240 milliliters) or as directed by your doctor. Do not lie down for at least 10 minutes after taking this drug.

Route of Administration: Oral

In Vitro Use Guide

Pidotimod 10 and 100 ug/ml increased TLR-2 expression in BEAS-2B cell line (human bronchial epithelial cells infected with a replication-defective Adenovirus 12-SV40 virus hybrid)

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:29:40 GMT 2025` Edited by `admin` on `Wed Apr 02 09:29:40 GMT 2025`
Record UNII	785363R681
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PIDOTIMOD

Official Name

English

PILIMOD

Preferred Name

English

Pidotimod [WHO-DD]

Common Name

English

(R)-3-((S)-5-OXOPROLYL)-4-THIAZOLIDINECARBOXYLIC ACID

Systematic Name

English

NSC-759841

Code

English

PIDOTIMOD [MART.]

Common Name

English

PIDOTIMOD [MI]

Common Name

English

pidotimod [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QL03AX05